Overview

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare any good and bad effects the study drug atezolizumab has on the cancer when combined with the standard chemotherapy drugs gemcitabine and cisplatin (or GC) in two different dosing schedules: chemotherapy (GC) before atezolizumab vs. GC after atezolizumab.

Phase:

Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborators:

Genentech, Inc.
Ohio State University
Targos
University of Chicago

Treatments:

Antibodies, Monoclonal
Atezolizumab
Cisplatin
Gemcitabine